TVTX- Travere Therapeutics, Inc.
Travere Therapeutics, Inc. (TVTX) has 16 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. TVTX is classified in the Biotechnology industry within the Health Care sector.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 440.1K | $19.61M | -64,000 | |
| Other | 138.6K | $6.17M | - | |
| Other | 123.1K | $5.48M | - | |
| CFO | 116.9K | $5.21M | -1,014 | |
| Other | 111.5K | $4.97M | -1,018 |
Activity
Buys and sells only
Transactions
10 filings · page 9
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 23, 2024 | Calvin Sandra60 | SVP, Chief Accounting Officer | Sell | 910 | $9.07 | $8,252.24 | -2.2% | -37.0% | +109.5% | |
| Jan 23, 2024 | Heerma Peter53 | Chief Commercial Officer | Sell | 1,559 | $9.07 | $14,137.64 | -1.9% | -37.0% | +109.5% | |
| Jan 4, 2024 | Inrig Jula45 | Chief Medical Officer | Sell | 2,509 | $9.43 | $23,647.68 | -3.4% | -23.2% | +107.5% | |
| Oct 3, 2023 | Heerma Peter53 | Chief Commercial Officer | Sell | 3,091 | $8.25 | $25,504.15 | -3.7% | +11.8% | +62.2% | |
| Sep 5, 2023 | Cline Christopher R.50 | Chief Financial Officer | Sell | 457 | $14.71 | $6,722.56 | -0.9% | -55.7% | -29.2% | |
| Sep 5, 2023 | Reed Elizabeth E58 | SVP, GC &Corporate Secretary | Sell | 1,815 | $14.71 | $26,698.65 | -3.0% | -55.7% | -29.2% | |
| Sep 5, 2023 | Dube Eric M57 | Chief Executive Officer | Sell | 4,455 | $14.71 | $65,533.05 | -1.8% | -55.7% | -29.2% | |
| Sep 5, 2023 | Rote William E.58 | Senior Vice President, R&D | Sell | 1,815 | $14.71 | $26,698.65 | -2.9% | -55.7% | -29.2% | |
| May 11, 2023 | Calvin Sandra60 | SVP, Chief Accounting Officer | Sell | 558 | $16.49 | $9,199.88 | -0.7% | -5.6% | -61.0% | |
| May 10, 2023 | Cline Christopher R.50 | Chief Financial Officer | Sell | 455 | $16.59 | $7,548.45 | -0.9% | -4.8% | -59.5% |